Loading
Life sciences · Journal article
BMC Complementary Medicine and Therapies · September 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Obesity represents a significant global health challenge resulting from the intricate interactions between genetic predispositions, environmental influences, and lifestyle choices, ultimately causing abnormal fat accumulation. Glycyrrhiza uralensis, a plant traditionally used in Asian herbal medicine, has anti-inflammatory and antioxidant properties and has been reported to influence metabolic processes. Gancaonin N (GN), a prenylated isoflavone derived from G. uralensis, has not been investigated for its potential effects on adipogenesis and lipid metabolism. Methods This study employed a combined approach using network pharmacology and in vitro validation in 3T3-L1 adipocytes. Network pharmacology was used to predict GN-related targets, identify overlapping genes with obesity, and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Subsequently, 3T3-L1 preadipocytes were treated with GN to evaluate its effects on adipocyte differentiation and lipid accumulation. Oil Red O staining, Western blotting, and PCR analyses were conducted to assess adipogenesis and lipid metabolism related pathways. Results Network pharmacology analysis identified 17 overlapping targets between GN-related and obesity-related genes, with key hub genes including peroxisome proliferator-activated receptor γ (PPARγ) and fatty acid synthase (FASN). GO and KEGG enrichment analyses suggested that GN is associated with pathways related to lipid metabolism, adipogenesis, and AMP-activated protein kinase (AMPK) signaling. To validate these predictions, 3T3-L1 cells were treated with GN. Adipocyte differentiation and lipid accumulation were significantly inhibited in a concentration-dependent manner, as demonstrated by Oil Red O staining. Western blot and PCR analyses revealed downregulation of key adipogenic regulators, including PPARγ, CCAAT/enhancer-binding protein α (C/EBPα), and sterol regulatory element-binding protein 1c (SREBP-1c), as well as suppression of lipogenic genes such as FASN and FABP4. Moreover, GN was associated with activation of AMPK, a central regulator of energy homeostasis and fatty acid oxidation. Conclusions These findings suggest that GN may regulate adipocyte differentiation and lipid metabolism through multiple signaling pathways.